drugset / Trial / NCT00792714

Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients

NCT00792714

Phase 1 Completed 18 enrolled Syntara
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The general objective of the study is to estimate the systemic pharmacokinetics of mannitol after single and multiple dosing of IDPM 400 mg to adult and paediatric cystic fibrosis patients.

Timeline

Start
2008-12
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent 400 mg Inhaled

Indications